Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Investigative Radiology|January 19, 2013
Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancerDiederik M Somford, Caroline M Hoeks, Christina A Hulsbergen-van de Kaa, et al.
Familial Cancer|May 9, 2024
Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relativesMichiel Vlaming, Margreet G E M Ausems, Gina Schijven, et al.
Radiology|September 21, 2011
Prostate cancer: multiparametric MR imaging for detection, localization, and stagingCaroline M A Hoeks, Jelle O Barentsz, Thomas Hambrock, et al.
European Urology|June 7, 2021
A Quantitative Analysis Investigating the Prevalence of "Manels" in Major Urology MeetingsJeremy Yuen-Chun Teoh, Daniele Castellani, Claudia Mercader, et al.
Clinical Genitourinary Cancer|May 10, 2023
Tumoral Ki67 and PSMA Expression in Fresh Pre-PSMA-RLT Biopsies and Its Relation With PSMA-PET Imaging and Outcomes of PSMA-RLT in Patients With mCRPCBabette I Laarhuis, Marcel J R Janssen, Michiel Simons, et al.
European Urology Focus|January 15, 2018
Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-upEsther Hendrika Johanna Hamoen, Caroline M A Hoeks, Diederik M Somford, et al.
Molecular Oncology|March 2, 2021
Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatmentEmmy Boerrigter, Guillemette E Benoist, Inge M van Oort, et al.
Urologic Oncology|August 19, 2014
Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patientsGuillaume Ploussard, Hendrik Isbarn, Alberto Briganti, et al.
Investigative Radiology|November 14, 2013
Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort studyCaroline M A Hoeks, Diederik M Somford, Inge M van Oort, et al.
Cancer|January 3, 2014
Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatmentSushil Badrising, Vincent van der Noort, Inge M van Oort, et al.
Pageof 14